Kadence Bio is a clinical-stage life sciences company developing novel therapeutics for sexual and mental health conditions. The company is advancing KH-001 as the first potential FDA-approved treatment specifically for premature ejaculation. Its pipeline also includes compounds aimed at addressing various mood disorders.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Premature ejaculation (PE) affects a significant portion of men globally, leading to decreased sexual satisfaction, personal distress, and relationship problems for both the individual and their partners. Current treatment options are limited, with no FDA-approved pharmacological treatments available in the US. This lack of effective and approved treatments leaves a substantial unmet need in the market.
Solution
Kadence Bio is a clinical-stage biopharmaceutical company focused on developing novel, fast-acting small molecule therapeutics to address unmet needs in sexual and mental health. Their lead asset, KH-001, is being developed as the first FDA-approved on-demand oral treatment for premature ejaculation. KH-001 has demonstrated promising results in animal studies and has completed a Phase 1 clinical trial, with Phase 2 trials planned to begin in 2025. The company aims to bridge the "intimacy gap" by improving ejaculatory control, self-esteem, mental wellbeing, and relationship health for both partners.
Target Audience
The primary target audience includes men experiencing premature ejaculation and their partners, as well as healthcare providers specializing in sexual health and mental wellbeing.
Features
- KH-001: A proprietary, on-demand, orally-administered small molecule
- Targets premature ejaculation, with the goal of becoming the first FDA-approved treatment
- Completed Phase 1 clinical trial demonstrating safety and characterizing pharmacokinetics
- Phase 2 proof-of-concept efficacy trials planned for 2025
- Developing proprietary new chemical entities (NCEs) to target a range of neuropsychiatric disorders
- Benefit-sharing agreement with the South African San Council (SASC) under the Nagoya Protocol, ensuring fair and equitable sharing of benefits from the use of indigenous knowledge